Half-year report · Q2
4574.TEDINET S100WI6C
Period2025-01-01 → 2025-06-30
Filed2025-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥6.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥482m | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥688m | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥528m | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥724m | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥898m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥12.9bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥13.4bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.7bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥4.9bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥8.1bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.2bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥362m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥256m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥135m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥562m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.9 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.24 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
| Otherother segments | revenue | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | segment profit | 2024-01-01 → 2024-06-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥401m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥195m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-06-30 | ¥884m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 523
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for loss on subleases ncl | Prior1YearInstant | 15000000 | JPY |
| Provision for loss on subleases ncl | CurrentQuarterInstant | 10000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 655000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 669000000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 20000000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 20000000 | JPY |
| Other ncl | Prior1YearInstant | 60000000 | JPY |
| Other ncl | CurrentQuarterInstant | 71000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 2094000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 1440000000 | JPY |
| Liabilities | Prior1YearInstant | 4949000000 | JPY |
| Liabilities | CurrentQuarterInstant | 3731000000 | JPY |
| Capital stock | Prior1YearInstant | 10000000 | JPY |
| Capital stock | CurrentQuarterInstant | 10000000 | JPY |
| Capital surplus | Prior1YearInstant | 4997000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 4978000000 | JPY |
| Retained earnings | Prior1YearInstant | 2526000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 2806000000 | JPY |
| Treasury stock | Prior1YearInstant | -273000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -237000000 | JPY |
| Shareholders equity | Prior1YearInstant | 7260000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 7557000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 234000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | － | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 468000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | 391000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 703000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 391000000 | JPY |
| Net assets | Prior1YearInstant | 7964000000 | JPY |
| Net assets | CurrentQuarterInstant | 7948000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 12914000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 11680000000 | JPY |
| Net sales | Prior1YTDDuration | 2860000000 | JPY |
| Net sales | CurrentYTDDuration | 2412000000 | JPY |
| Cost of sales | Prior1YTDDuration | 1181000000 | JPY |
| Cost of sales | CurrentYTDDuration | 1091000000 | JPY |
| Gross profit | Prior1YTDDuration | 1678000000 | JPY |
| Gross profit | CurrentYTDDuration | 1320000000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 1196000000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 1273000000 | JPY |
| Operating income | Prior1YTDDuration | 482000000 | JPY |
| Operating income | CurrentYTDDuration | 46000000 | JPY |
| Interest income noi | Prior1YTDDuration | 15000000 | JPY |
| Interest income noi | CurrentYTDDuration | 7000000 | JPY |
| Foreign exchange gains noi | Prior1YTDDuration | 38000000 | JPY |
| Foreign exchange gains noi | CurrentYTDDuration | － | JPY |
| Insurance income noi | Prior1YTDDuration | 1000000 | JPY |
| Insurance income noi | CurrentYTDDuration | 1000000 | JPY |
| Subsidy income noi bounty | Prior1YTDDuration | － | JPY |
| Subsidy income noi bounty | CurrentYTDDuration | 3000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |